Renovaro to acquire AI health company GEDi Cube in stock-for-stock deal; combined company to focus on precision medicine

Lunai Bioworks Inc.

GEDi Cube holders to receive ~50% of Renovaro common stock (subject to adjustments); supermajority (78%) of GEDi holders support deal.
Transaction expected to close late Q4 2023 or early 2024, subject to Renovaro shareholder approval and other conditions.
Combined company plans to launch AI-based commercial diagnostic products in 2024; Renovaro aims to start Phase 1/2 pancreatic cancer trial in H2 2024.
GEDi Cube validated early lung cancer diagnosis at a university hospital; technology targets 12 additional cancers including pancreatic and breast.
Renovaro's pre-clinical and clinical data expected to accelerate GEDi's AI, which in turn could advance Renovaro's therapy development.

item 1.01 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lunai Bioworks Inc. entered into Purchase Agreement with GEDi Cube Intl Ltd. (effective 2023-09-28).

Action: entry
Agreement: merger
Counterparty: GEDi Cube Intl Ltd.
Effective: 2023-09-28

Exact text from the filing

On September 28, 2023, Renovaro Biosciences Inc. (NASDAQ: RENB) (“ Renovaro ”), entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) with GEDi Cube Intl Ltd.

View on SEC.gov

280 material agreements filed in the last 30 days. Browse all material agreements →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR

accession 0001731122-23-001762

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.